Free Trial

Bioqual Q4 2024 Earnings Report

Bioqual logo
$62.50 -2.50 (-3.85%)
As of 01/21/2025 10:27 AM Eastern

Bioqual EPS Results

Actual EPS
-$1.32
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$11.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioqual Announcement Details

Quarter
Q4 2024
Time
N/A

Conference Call Resources

Bioqual Earnings Headlines

BIOQUAL Announces Changes to Board of Directors
Kamala’s final humiliation
Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behind closed doors with some of America’s savviest investors. The obscure, little-known companies we believe could 5x, even 10x, under Trump’s second term…
BIOQUAL Declares Dividend
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ) provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

View Bioqual Profile

More Earnings Resources from MarketBeat